retatrutide clinical trials results weight loss Effects of once-weekly subcutaneous on and metabolic markers: A systematic review and meta-analysis of randomized controlled Looking forward to when #retatrutide's

SGLT-2

News Release: Lilly's oral GLP-1, orforglipron, demonstrated statistically significant efficacy results and a safety profile consistent with injectable GLP-1 medicines in successful Phase 3 trial

Recent advances in mechanisms regulating glucose oxidation at the level of the pyruvate dehydrogenase complex by PDKs

One recent study in patients with psoriasis and psoriatic arthritis found that overweight individuals who combined a GLP-1 agonist with an anti-IL-17 medication experienced both weight loss and improved disease control compared to those using immunosuppressive therapy alone

Compounded semaglutide is not FDA-approved or regulated and carries significant safety risks due to purity and dosing issues

Loss of BMAL1 disrupts circadian cytokine oscillations and prolongs inflammatory responses